6 analysts have expressed a variety of opinions on Pharming PHAR over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides a quick overview of ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease.

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a ...

Jefferies initiated coverage of Pharming (PHAR) with a Buy rating and $14 price target The firm believes the market is either underappreciating the Joenja opportunity treating rare disease ...

Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to ...